HeartBeat.bio is building the worldwide first high-throughput human organoid cultivation, screening and AI-supported data analysis solution for developing first-in-class drugs to treat heart failure faster, less expensively and with a higher probability of success in clinical trials. Here are details of HeartBeat‘s latest funding round :
🚀 Launch
2021
🏭 Industry
Biotechnology
🧠Management
Michael Krebs (CEO)
💸 Funding & Investors
| INVESTMENT (Novembre 2023) | €4.5 million (Seed) |
| INVESTORS (Novembre 2023) | led by i&i Biotech Fund, Invest AG, aws Gründungsfonds II, and Tensor Ventures. |
🎯 Funding purpose
Enable the completion of a cardioid drug discovery platform for proprietary and collaborative drug discovery programs in indications such as drug-induced and genetic cardiomyopathies, as well as myocardial infarction and fibrosis.
🌐 Country HQ
Austria (Vienna)